Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risks of metabolic syndrome in the ADVANCE and NAMSAL trials.
Tovar Sanchez T, Mpoudi-Etame M, Kouanfack C, Delaporte E, Calmy A, Venter F, Sokhela S, Bosch B, Akpomiemie G, Tembo A, Pepperrell T, Simmons B, Casas CP, McCann K, Mirchandani M, Hill A. Tovar Sanchez T, et al. Among authors: mirchandani m. Front Reprod Health. 2023 Sep 18;5:1133556. doi: 10.3389/frph.2023.1133556. eCollection 2023. Front Reprod Health. 2023. PMID: 37791109 Free PMC article.
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Bosch B, Akpomiemie G, Chandiwana N, Sokhela S, Hill A, McCann K, Qavi A, Mirchandani M, Venter WDF. Bosch B, et al. Among authors: mirchandani m. Clin Infect Dis. 2023 Apr 17;76(8):1492-1495. doi: 10.1093/cid/ciac949. Clin Infect Dis. 2023. PMID: 36519389 Clinical Trial.
Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa.
Sokhela S, Bosch B, Hill A, Simmons B, Woods J, Johnstone H, Madhi S, Qavi A, Ellis L, Akpomiemie G, Bhaskar E, Levi J, Falconer J, Mirchandani M, Perez Casas C, Moller K, Pilkington V, Pepperrell T, Venter WDF. Sokhela S, et al. Among authors: mirchandani m. Open Forum Infect Dis. 2022 Dec 16;9(12):ofac587. doi: 10.1093/ofid/ofac587. eCollection 2022 Dec. Open Forum Infect Dis. 2022. PMID: 36540387 Free PMC article.
Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud.
Hill A, Mirchandani M, Pilkington V. Hill A, et al. Among authors: mirchandani m. Open Forum Infect Dis. 2022 Jan 17;9(2):ofab645. doi: 10.1093/ofid/ofab645. eCollection 2022 Feb. Open Forum Infect Dis. 2022. PMID: 35071686 Free PMC article.
Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials.
Rezai MS, Ahangarkani F, Hill A, Ellis L, Mirchandani M, Davoudi A, Eslami G, Roozbeh F, Babamahmoodi F, Rouhani N, Alikhani A, Najafi N, Ghasemian R, Mehravaran H, Hajialibeig A, Navaeifar MR, Shahbaznejad L, Rahimzadeh G, Saeedi M, Alizadeh-Navai R, Moosazadeh M, Saeedi S, Razavi-Amoli SK, Rezai S, Rostami-Maskopaee F, Hosseinzadeh F, Movahedi FS, Markowitz JS, Valadan R. Rezai MS, et al. Among authors: mirchandani m. Front Med (Lausanne). 2022 Jun 16;9:919708. doi: 10.3389/fmed.2022.919708. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35783616 Free PMC article.
17 results